Two B or not two B; the question of bendamustine dosing in low grade lymphoma.

Pathol Oncol Res · 2025 · PMC12507707 · PMID 41078580

Europe PMC DOI

hedged sentence

0.0810

closest p · 1.6× alpha

0.0810

boldest claim

The sentences

did not reach statistical significancep = 0.081so close (0.05 < p ≤ 0.1)

In contrast, among those treated with Bendamustine in the second-line or later setting, although differences in PFS and OS ( Figures 2B,D ) did not reach statistical significance, patients receiving the 1-day dosing regimen demonstrated a trend toward improved outcomes in both PFS and OS (p = 0.081, p = 0.230).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.